Excellent Long Term Safety and Efficacy Sustained safety and efficacy for at least 3 years in 5400 real-world patients Cardiac Death Ordering Information * MACE: A Composite of cardiac death, MI, or clinically indicated TVR Event Rate (%) POCE: MACE: ci-TVR: CD: STEMI: IDDM: CTO: RRR: Composition of all death, all MI, all revascularization Composite of cardiac death, MI (target vessel MI in COMFORTABLE AMI study), ci-TVR Clinically indicated Target Vessel Revascularization Cardiac Death ST-elevated Myocardial Infarction Insulin-dependent Diabetes Mellitus Chronic Total Occlusion Relative Risk Reduction MACE@5 yrs Landmark @30 days LEADERS RRR=70% SYNTAX SCORE >12 MACE@5 yrs LEADERS RRR=29% Lowest very late stent thrombosis in all-comer trials9 Biosensors International internal bench testing performed on 3.0 mm stents. Data on file at Biosensors International Percentage change in stent length after applying 5N compression force longitudinally Recoil measured as percentage change in diameter at RBP ﬔis data is related to BioMatrix Family, which has the exact same coating and equivalent pharmacokinetics as BioMatrix Alpha Hildick-Smith D et al. EuroPCR 2015 Windecker S et al. Lancet. 2008; 372:1163-73 Serruys PW, et al. JACC Cardiovasc Interv. 2013; 6:777-89 Räber L, et al. Circ Cardiovasc Interv. 2014; 7:355-64 Stefanini G, Windecker S. Circulation Card Intv 2012; 5:332-5 De Cock D, et al. Cardiovascular Imaging. 2014; 15-900-09 Lüscher TF, et al. Circulation. 2007; 115:1051-58 Farb A, et al. Circulation. 2003; 108:1701–06 Joner M, et al. J Am Coll Cardiol. 2006; 48:193-202 Gladden LB. J Physiol. 2004; 558(1):5-30 Ghani, QP. et al. Methods in Enzymology. 2004; 381(36):565-75 Granada JF, SOLACI-CACI 2014 BioMatrix Alpha™ drug eluting stent system is CE approved. CAUTION: ﬔe law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. Event Rate (%) Rates of very late definite stent thrombosis in all-comers randomized trials comparing DES at 3 years of follow-up9 Superior long term outcomes in complex real-world patients Low cardiac death rate at 3 years (2.1%) Low myocardial infarction rate at 3 years (3.2%) Low target vessel revascularization rate at 3 years (5.6%) Low composite MACE rate at 3 years (9%) BioMatrix NeoFlex, BioMatrix Flex, Juno, Quadrature Link, Biolimus A9 and BA9 are trademarks or registered trademarks of Biosensors International Group, Ltd. All cited trademarks are the property of their respective owners. Not available for sale in the United States and certain other countries. © 2016. Biosensors International Group, Ltd. All rights reserved. www.biosensors.com BIOSENSORS EUROPE SA Over 20'300 patients have been treated with BioMatrix Family stents in various randomized controlled trials BIOSENSORS INTERVENTIONAL TECHNOLOGIES PTE LTD 36 Jalan Tukang Singapore 619266 Tel: +65 6213 5777 Fax: +65 6213 5737 Event Rate (%) A very large international prospective registry5 of the BioMatrix Family of stents in unselected patients demo

Unmatched longitudinal strength Proximal and distal straight connectors Biolimus A9TM Designed for Vascular Technology Not All Limus Drugs are the Same 100 10 times more lipophilicity than Sirolimus Slower metabolism of drug due to its structure High local bioavailability High flexibility Mid section S-shape connectors BioMatrix Alpha Power to Heal Excellent deliverability Excellent trackability and pushability together with low tip entry profile Relative Lipophilicity (%) BioMatrix Alpha Stent Platform TM High strength and radiopacity ﬔin strut cobalt chromium without any compromise on radial...